Production (Stage)
Artiva Biotherapeutics, Inc.
ARTV
$1.95
-$0.03-1.52%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Total Cash And Short-Term Investments | 165.96M | 185.43M | 146.63M | 46.56M | 62.13M |
| Total Receivables | 234.00K | 1.19M | 1.40M | 1.56M | 1.72M |
| Inventory | -- | -- | -- | -- | -- |
| Prepaid Expenses | 3.81M | 5.21M | 2.53M | 1.63M | 2.03M |
| Finance Division Loans and Leases Current | -- | -- | -- | -- | -- |
| Total Finance Division Other Current Assets | -- | -- | -- | -- | -- |
| Other Current Assets | -- | -- | -- | -- | -- |
| Total Current Assets | 170.00M | 188.63M | 150.57M | 49.75M | 65.89M |
|
|
|||||
| Total Current Assets | 170.00M | 188.63M | 150.57M | 49.75M | 65.89M |
| Net Property, Plant & Equipment | 20.79M | 20.43M | 21.51M | 22.74M | 23.37M |
| Long-term Investments | -- | -- | -- | -- | -- |
| Goodwill | -- | -- | -- | -- | -- |
| Total Other Intangibles | -- | -- | -- | -- | -- |
| Finance Div Loans & Leases LT | -- | -- | -- | -- | -- |
| Total Finance Div Other LT Assets | -- | -- | -- | -- | -- |
| Total Other Assets | 474.00K | 525.00K | 556.00K | 3.43M | 905.00K |
| Total Assets | 191.26M | 209.58M | 225.60M | 75.91M | 90.16M |
|
|
|||||
| Total Accounts Payable | 2.04M | 1.12M | 1.22M | 823.00K | 1.48M |
| Total Accrued Expenses | 6.38M | 7.39M | 8.34M | 6.21M | 5.24M |
| Short-term Debt | -- | -- | -- | -- | -- |
| Current Portion of Long-Term Debt/Capital Leases | -- | -- | -- | -- | -- |
| Finance Division Debt Current | 3.72M | 3.74M | 3.73M | 3.79M | 3.65M |
| Total Finance Division Other Current Liabilities | 73.00K | -- | -- | -- | -- |
| Total Other Current Liabilities | 73.00K | -- | -- | -- | -- |
| Total Current Liabilities | 12.20M | 12.25M | 13.29M | 10.83M | 10.37M |
|
|
|||||
| Total Current Liabilities | 12.20M | 12.25M | 13.29M | 10.83M | 10.37M |
| Long-Term Debt | -- | -- | -- | -- | -- |
| Short-term Debt | -- | -- | -- | -- | -- |
| Capital Leases | 10.28M | 10.61M | 11.24M | 11.98M | 12.61M |
| Finance Division Debt Non Current | -- | -- | -- | -- | -- |
| Total Finance Division Other Non Current Liabilities | -- | -- | -- | -- | -- |
| Total Other Liabilities | -- | 73.00K | 73.00K | 27.79M | 25.44M |
| Total Liabilities | 22.48M | 22.94M | 24.60M | 50.60M | 48.42M |
|
|
|||||
| Common Stock & APIC | 435.78M | 433.45M | 431.25M | 21.90M | 20.39M |
| Retained Earnings | -267.00M | -246.68M | -230.59M | -213.12M | -195.27M |
| Treasury Stock & Other | -- | -129.00K | 338.00K | 121.00K | 207.00K |
| Total Common Equity | 168.78M | 186.64M | 201.00M | -191.10M | -174.67M |
|
|
|||||
| Preferred Stock Redeemable | -- | -- | -- | -- | -- |
| Preferred Stock Non Redeemable | -- | -- | -- | -- | -- |
| Preferred Stock Convertible | -- | -- | -- | 216.41M | 216.41M |
| Preferred Stock, Others | -- | -- | -- | -- | -- |
| Total Preferred Equity | -- | -- | -- | 216.41M | 216.41M |
|
|
|||||
| Total Common Equity | 168.78M | 186.64M | 201.00M | -191.10M | -174.67M |
| Total Preferred Equity | -- | -- | -- | 216.41M | 216.41M |
| Total Minority Interest | -- | -- | -- | -- | -- |
| Total Equity | 168.78M | 186.64M | 201.00M | 25.32M | 41.74M |
|
|
|||||